Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – What’s Next?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) gapped down prior to trading on Friday . The stock had previously closed at $10.15, but opened at $9.85. Amicus Therapeutics shares last traded at $9.59, with a volume of 205,998 shares.

Analysts Set New Price Targets

A number of research analysts have recently commented on FOLD shares. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Bank of America boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 10th. Finally, Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Stock Performance

The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company has a fifty day moving average price of $10.52 and a 200 day moving average price of $10.61. The stock has a market cap of $2.80 billion, a PE ratio of -27.53 and a beta of 0.60.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. This represents a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 30,401 shares of company stock valued at $339,363. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. increased its position in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. raised its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.